From Nvidia:

1. Amgen, a leading biotechnology company, will use AI technology to accelerate their research. The company will build AI models using an NVIDIA DGX SuperPOD at their deCODE genetics’ headquarters in Reykjavik, Iceland, to develop a human diversity atlas for drug target and disease-specific biomarker discovery.

2. The system, named “Freyja,” will train models in days, not months, using 31 NVIDIA DGX H100 nodes and 248 H100 Tensor Core GPUs. Amgen plans to efficiently analyze and learn from data to discover novel health and therapeutics insights.

3. The goal is to integrate advanced AI with human data capabilities to explore uncommon diseases through genetics. The company aims to leverage technology and biotechnology to reshape medicine and drug discovery for the future.

4. deCODE, founded in 1996, has curated over 200 petabytes of de-identified human data from nearly 3 million individuals. Having integrated NVIDIA BioNeMo, Amgen aims to accelerate drug discovery and development.

5. By leveraging advanced AI models, Amgen plans to develop more effective drugs while avoiding unwanted effects like immune responses, and producing new biologics in volume. The goal is to reshape medicine and drug discovery for the future.



Read more: Amgen to Build Generative AI Models for Drug Discovery